TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy.

Grivas P, Tagawa ST, Bellmunt J, De Santis M, Duran I, Goebell P, Necchi A, Sridhar SS, Sternberg CN, Aziz UM, Pichardo CC, Loriot Y (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Journal of Clinical Oncology American Society of Clinical Oncology

Publisher: LIPPINCOTT WILLIAMS & WILKINS

City/Town: PHILADELPHIA

Conference Proceedings Title: JOURNAL OF CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2021.39.6_suppl.TPS498

Authors with CRIS profile

Peter Goebell Urologische Klinik

Involved external institutions

Immunomedics, Inc

United States (USA) (US) Cornell University

United States (USA) (US) École Polytechnique - Université Paris-Saclay

France (FR) University of Toronto

Canada (CA) Beth Israel Deaconess Medical Center (BIDMC)

United States (USA) (US) Fondazione IRCCS: Istituto Nazionale dei Tumori

Italy (IT) Marqués de Valdecilla University Hospital / Hospital Universitario de Marqués de Valdecilla (HUMV)

Spain (ES) Charité - Universitätsmedizin Berlin

Germany (DE) Seattle Cancer Care Alliance

United States (USA) (US)

How to cite

APA:

Grivas, P., Tagawa, S.T., Bellmunt, J., De Santis, M., Duran, I., Goebell, P.,... Loriot, Y. (2021). TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. In JOURNAL OF CLINICAL ONCOLOGY. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

MLA:

Grivas, Petros, et al. "TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy." Proceedings of the JOURNAL OF CLINICAL ONCOLOGY PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2021.

BibTeX: Download